|Amlodipine + Valsartan + Hydrochlorothiazide|
Triforge is a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic.
Triforge is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes, and myocardial infarctions.
DOSAGE & ADMINISTRATION:
Dose once-daily. Titrate up to a maximum dose of 10/320/25 mg, TRIFORGE may be used as add-on/switch therapy for patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics.
Anuria, Hypersensitivity to sulfonamide-derived drugs, Known hypersensitivity to any component of this drug.
Increased angina and/or myocardial infarction, Impaired renal function hypersensitivity reaction, Systemic Lupus Erythematosus, Lithium interaction, Potassium abnormalities, Acute Myopia and secondary angle-closure glaucoma, Metabolic imbalances, Hypotension in Volume- or- salt- Depleted Patients angle-closure glaucoma.
Most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.
Tablets:(amlodipine/valsartan/hydrochlorothiazide mg) 5/160/12.5, 10/160/12.5, 5/160/25, 10/160/25, 10/320/25.